Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | TARS1 | P26639 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | ACACA | Q13085 | 2/20 | 0.32 |
| ▸ | GLS | O94925 | 2/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30941254 | 0.94 | BRD4 (0.36) | CHKABRD4CYP2D6ROCK2CREBBP | |
| SCHEMBL25047831 | 0.88 | METTL3 (0.41) | CHKABRD4CYP2D6ROCK2CREBBP | |
| SCHEMBL30941032 | 0.86 | PRMT5 (0.40) | BRD4CYP2D6ROCK2CREBBPGLS | |
| SCHEMBL25047726 | 0.84 | PRMT5 (0.36) | NT5E | |
| SCHEMBL25046572 | 0.84 | METTL3 (0.37) | CHKABRD4CYP2D6ROCK2CREBBP | |
| SCHEMBL30941558 | 0.83 | CHKA (0.32) | CHKAROCK2ACACBACACA | |
| SCHEMBL25048316 | 0.82 | HTR2C (0.34) | GLS | |
| SCHEMBL30941316 | 0.81 | PRMT5 (0.38) | BRD4CYP3A4 | |
| SCHEMBL30941531 | 0.79 | CCNE2 (0.35) | BRD4ROCK2 | |
| SCHEMBL30941297 | 0.78 | AURKA (0.38) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | CHKA 807/4885NT5E 2836/4885BRD4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.